Verastem (VSTM) says it has completed the dose escalation portion of a Phase 1/ 1b trial of...

|About: Verastem (VSTM)|By:, SA News Editor

Verastem (VSTM) says it has completed the dose escalation portion of a Phase 1/ 1b trial of VS-6063 and paclitaxel in ovarian cancer patients. The anticipated Phase 2 dose of VS-6063 was reached "without any dose-limiting toxicities" and three out of six patients experienced a "significant" reduction in the marker that becomes elevated when the disease has progressed. (PR)